Neuronetics (STIM)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (0.00%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Neuronetics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 61 | 72 | 96 | 51 | 77 |
Receivables | 18 | 14 | 8 | 7 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 9 | 7 | 4 | 3 |
Other Current Assets | 7 | 4 | 5 | 3 | 3 |
Total Current Assets | 94 | 99 | 115 | 65 | 88 |
Net Property & Equipment | 2 | 2 | 1 | 1 | 1 |
Investments & Advances | 1 | 1 | 2 | 2 | 2 |
Other Non-Current Assets | 4 | 0 | 10 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 13 | 11 | 9 | 7 | 5 |
Total Assets | 116 | 117 | 141 | 79 | 100 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 2 | 4 | 4 | 5 |
Current Portion Long-Term Debt | 0 | 13 | 0 | 0 | 11 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 15 | 8 | 7 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 3 | 2 | 2 |
Total Current Liabilities | 20 | 33 | 16 | 14 | 28 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 1 | 1 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 59 | 23 | 35 | 35 | 20 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 82 | 60 | 56 | 53 | 52 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 410 | 403 | 394 | 303 | 298 |
Retained Earnings | -376 | -346 | -309 | -278 | -250 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 34 | 57 | 85 | 25 | 48 |
Total Liabilities & Shareholder's Equity | 116 | 117 | 141 | 79 | 100 |
Total Common Equity | 34 | 57 | 85 | 25 | 48 |
Shares Outstanding | 28.90 | 27.20 | 26.30 | 19.10 | 18.60 |
Book Value Per Share | 1.18 | 2.10 | 3.24 | 1.33 | 2.57 |
Fiscal Year End for Neuronetics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 43 | 49 | 61 | 37 | 47 |
Receivables | 20 | 20 | 18 | 17 | 15 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 7 | 8 | 10 | 9 |
Other Current Assets | 7 | 7 | 7 | 8 | 7 |
Total Current Assets | 76 | 82 | 94 | 71 | 78 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 1 | 1 | 1 | 1 |
Other Non-Current Assets | 3 | 4 | 4 | 4 | 5 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 14 | 13 | 13 | 12 | 12 |
Total Assets | 97 | 104 | 116 | 93 | 100 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 5 | 3 | 4 |
Current Portion Long-Term Debt | 14 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 9 | 13 | 10 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 2 | 2 | 2 |
Total Current Liabilities | 29 | 15 | 20 | 15 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 46 | 59 | 59 | 37 | 37 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 77 | 76 | 82 | 55 | 55 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 413 | 411 | 410 | 408 | 407 |
Retained Earnings | -394 | -384 | -376 | -371 | -361 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 19 | 28 | 34 | 38 | 45 |
Total Liabilities & Shareholder's Equity | 97 | 104 | 116 | 93 | 100 |
Total Common Equity | 19 | 28 | 34 | 38 | 45 |
Shares Outstanding | 30.00 | 29.90 | 28.90 | 28.80 | 28.40 |
Book Value Per Share | 0.65 | 0.93 | 1.18 | 1.32 | 1.60 |